Navigation Links
Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

In vitro microbiology and proof of concept in topical models of infection

REINACH / BASEL, Switzerland, 8 March 2007 - Arpida Ltd. (SWX: ARPN) today announced positive results of in vitro microbiological studies with AR-2474 against a large panel of clinical isolates, including those resistant to various current therapies. In addition, topical applications of AR-2474 were found to be highly effective in eradicating methicillin resistant Staphylococcus aureus (MRSA) in preclinical models of skin infection and nasal carriage. AR-2474 is a novel antibiotic that is not affected by mechanisms of resistance to other antibiotics, e.g. mupirocin, fusidic acid, erythromycin and clindamycin.

The microbiological studies investigated the activity of AR-2474 against a panel of bacteria known to cause topical infections, e.g., skin, eye etc. The study was performed on 100 clinical isolates with various resistance patterns. The panel included 21 MRSA, 27 coagulase-negative staphylococci (CNS), 24 group A streptococci (GAS) and 28 pneumococci. The compound exhibited potent activity against all of the isolates and this activity was unaffected by any pre-existing mechanism of resistance.

Additionally, AR-2474 has been shown to be bactericidal and exhibit little or no propensity for the development of resistance. The antibacterial activity and potency of AR-2474 was also confirmed in vivo against topical gold standard mupirocin (Bactroban®) in two distinct preclinical models of MRSA infection of the skin and MRSA nasal carriage. In both models, a preliminary topical formulation of AR-2474 was at least as efficacious as mupirocin. Dr. Sergio Lociuro, Head of Research at Arpida Ltd. commented, "AR-2474 originates from our own research discovery programs and has now progressed to an advanced pre-clinical stage of development. We aim to develop AR-2474 as a topical therapy for different indications including the prevention of MRSA transmission. In recent
'"/>




Page: 1 2 3

Related medicine technology :

1. Arpida Announces Promising Results of "First-In-Man" Studies With AR-709
2. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
3. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida adds novel antibiotic its preclinical pipeline
(Date:11/25/2009)...RNewswire-FirstCall/--Abaxis,Inc.(Nasdaq: ABAX ),a...oodanalysissystems,announcedtodaythatClintSeverson...21stAnnualPiperJaffrayHealthCareConferenceonWednes...heldattheNewYorkPalaceHotelinNewYorkCity. ,, A...rketsportablebloodanalysissystemsforuseinanyveteri...
(Date:11/25/2009)...Newswire/--CempraPharmaceuticalsInc.todayannounced...eofficer,willpresentatthePiperJaffray21stAnnualHea...eNewYorkPalaceHotelinNewYorkCity.Dr.Fernandeswillp...clinicalprogramsforthetreatmentofdrug-resistantpat...cals ,, Foundedin2006,CempraPharmaceuticalsisa...
(Date:11/25/2009)...,Nov.25/PRNewswire-FirstCall/--HeartWareInternatio...ndprovideroflessinvasive,miniaturizedcirculatorysu...ncedheartfailure,todayannouncedthatitisscheduledto...rayHealthCareConferenceat8:00amESTonWednesday,Dece...aceHotel,December1-2. ,, AlivewebcastoftheCompa...
Breaking Medicine Technology:Electrocardiogram Blip Signals Heart Trouble 49820 1Electrocardiogram Blip Signals Heart Trouble 49820 2Electrocardiogram Blip Signals Heart Trouble 49820 3Connextions Inc Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 49816 1Connextions Inc Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 49816 2Connextions Inc Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 49816 3Children 26apos 3Bs National Medical Center Honors The Children 26apos 3Bs Cancer Foundation for Commitment to Area Kids 49812 1Children 26apos 3Bs National Medical Center Honors The Children 26apos 3Bs Cancer Foundation for Commitment to Area Kids 49812 2Children 26apos 3Bs National Medical Center Honors The Children 26apos 3Bs Cancer Foundation for Commitment to Area Kids 49812 3
...NESS WIRE)--Jun 11, 2007 - Neurogen,Corporation (N...us,Phase 1 clinical studies for NG2-73, the Compan...ere presented today at the SLEEP,2007 Annual Meeti...(APSS) in Minneapolis, Minnesota. Two Phase 2b cli...ents are currently being,conducted by the Company....
...pact of Insomnia on Healthcare System and,Worker P...FirstCall/ -- Neurocrine,Biosciences, Inc. announc...s on the impact of chronic primary and transient,i... Professional,Sleep Societies (APSS) Annual Meetin...ntly under-diagnosed and puts a significant,strain...
Other Medicine Technology:Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 2Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 3Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 5
(Date:11/26/2009)...ntal (RTDental), a leading dental group practice i...nsion of its services to include LUMINEERS by a ce..., Durham, NC (PRWEB) -- Re... Dr. Doug Macmillan, an experienced LUMINEERS De...raining seminar. RTDental’s ability to fulf...
(Date:11/25/2009)...re/--WhenmostpeopleheartheacronymTMJ,theythinkofth...elptheyneed.TMJstandsfortheTemporal-MandibularJoin...thyourskull(temporalbone). ,, Themostcommonsymp...,clickingorpoppingofthejaw.Butmanyothersymptomscan...gue,sleepdisturbances,irritability,alossinfocus,ri...
(Date:11/25/2009)...entinelleMedicalInc.,aleadingmanufacturerofMagneti...ientificInc.,aleadingproviderofsoftwareenablingtec...st4DAdvancedVisualizationsoftware. ,, Thisinnov...ntbasedmedicalimagingofferinginthemarket.CalgarySc...ntaccess-requiringnosoftwaredownload,andrunsonanyM...
(Date:11/25/2009)...ewswire/--AnarticlebyJanetWoodcock,M.D.,directorof...ADifficultBalance-PainManagement,DrugSafety,andthe...urnalofMedicine. ,, (Logo: http://www.newscom.c...cle,WoodcockdiscussesFDAeffortstostrikeabalancebet...gingtherisksposedbyvariousanalgesics.Asexamples,sh...
(Date:11/25/2009)...ndPressJoinEfforttoEducate ,, MEMPHIS,Tenn.,No...BipolarFoundationandtheMedicAlertFoundationreceive...,whichisnowbeingwidelyacceptedasapreventivehealthc...larFoundationreceivedaproclamationofendorsementvia...sianaMitchLandrieu.TheNationalBipolarFoundationsta...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3
...ments may further increase the risk of breast and ...ose diseases. //Researchers offer new evidence tha...ionally used for gynecological complaints - as wel...le all the plants can successfully be used to ease...
...ould more than double their daily exercise time in...advised to aim for 35 minutes a day// of moderate ...ists at the University of Alabama at Birmingham no...ed for 60 per cent of the weight gain - with food ...
... Hyperactivity Disorder - ADHD - have underactive ..., thinking and planning. The abnormality was revea...researchers to look at the brains of children with...nghtened claims that the controversial disease has...
...he harm unhealthy habits do can motivate them to c...of studies on biomarkers indicators of health or ...n affect people's behaviour. They learned th...emselves. Other factors that are useful to know ar...
...ins the progress of a catastrophic conditions in o...62% of patients who undergo heart transplants deve...osclerosis, in the first three years after their s...study. Dr James Fang, who led the research, called...
...during pregnancy can increase a mother's risk of h...women who were very anxious// in the last three mo...al problems. Lead researcher Professor Vivet... a survey antenatal anxiety leads to the risk of h...
Other Medicine News:
Anti-MPO - ELISA (P-ANCA)
Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay (ELISA)
Iso-Insulin ELISA
RIDASCREEN Anti-RSV IgM Assay
Medicine Products: